BIU 3.0: Ulm University and Boehringer Ingelheim set new signs!

BIU 3.0: Ulm University and Boehringer Ingelheim set new signs!

The cooperation between the pharmaceutical company Boehringer Ingelheim and the University of Ulm goes into the next round: The “Boehringer Ingelheim Ulm University Biocenter” (BIU) will start its third term under the name BIU 3.0 from the beginning of 2025. This cooperation that has existed since 2011 will be continued by 2030, aims to transfer new findings from basic research directly into the development of innovative therapies, as the new BIU Biocenter spokeswoman Professor Pamela Fischer-Posovszky explains.

The BIU Biocenter is considered the unique model of success of a public-private partner-ship in the biomedical sector. Together, research projects on cardiovascular and metabolic diseases, neuropsychiatric clinical pictures and lung diseases are carried out. Professor Klaus-Michael Debatin, long-time spokesman for the BIU, emphasizes that this cooperation offers great opportunities for young scientists. The research teams have already drawn attention to themselves with impressive results such as the discovery of new biomarkers and therapy approaches that promise promising progress in diagnostics and treatment more frequently. The start of the project is scheduled for January 2025, with funding of up to 100,000 euros per year for set up main projects. More information can be found in the article on news.idw-online.de .